Logo image of CGEN

COMPUGEN LTD (CGEN) Stock Fundamental Analysis

NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD

1.59  -0.1 (-5.92%)

After market: 1.5995 +0.01 (+0.6%)

Fundamental Rating

4

Taking everything into account, CGEN scores 4 out of 10 in our fundamental rating. CGEN was compared to 557 industry peers in the Biotechnology industry. While CGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. CGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CGEN has reported negative net income.
In the past year CGEN had a positive cash flow from operations.
In the past 5 years CGEN always reported negative net income.
CGEN had negative operating cash flow in 4 of the past 5 years.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

CGEN's Return On Assets of -12.38% is amongst the best of the industry. CGEN outperforms 82.94% of its industry peers.
With an excellent Return On Equity value of -25.92%, CGEN belongs to the best of the industry, outperforming 80.97% of the companies in the same industry.
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROIC N/A
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CGEN has a better Gross Margin (71.54%) than 82.41% of its industry peers.
CGEN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for CGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CGEN has more shares outstanding
Compared to 5 years ago, CGEN has more shares outstanding
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.73, we must say that CGEN is in the distress zone and has some risk of bankruptcy.
CGEN has a Altman-Z score (-3.73) which is in line with its industry peers.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -3.73
ROIC/WACCN/A
WACC9.07%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CGEN has a Current Ratio of 5.26. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN has a Current ratio (5.26) which is in line with its industry peers.
CGEN has a Quick Ratio of 5.26. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN has a Quick ratio (5.26) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 5.26
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.79% over the past year.
CGEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.40%.
CGEN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.84% yearly.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-23.4%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.75%

3.2 Future

Based on estimates for the next years, CGEN will show a very negative growth in Earnings Per Share. The EPS will decrease by -13.08% on average per year.
Based on estimates for the next years, CGEN will show a decrease in Revenue. The Revenue will decrease by -1.06% on average per year.
EPS Next Y-22.72%
EPS Next 2Y-6.37%
EPS Next 3Y15.29%
EPS Next 5Y-13.08%
Revenue Next Year-66.37%
Revenue Next 2Y-4.04%
Revenue Next 3Y2.48%
Revenue Next 5Y-1.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGEN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CGEN is valued cheaper than 99.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.88
EV/EBITDA N/A
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

CGEN's earnings are expected to grow with 15.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.37%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

CGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (7/11/2025, 8:00:00 PM)

After market: 1.5995 +0.01 (+0.6%)

1.59

-0.1 (-5.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-19 2025-05-19/bmo
Earnings (Next)07-31 2025-07-31
Inst Owners18.11%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap142.37M
Analysts88
Price Target6.12 (284.91%)
Short Float %1.67%
Short Ratio6.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-142.14%
Min EPS beat(2)-193.59%
Max EPS beat(2)-90.69%
EPS beat(4)1
Avg EPS beat(4)-117.3%
Min EPS beat(4)-256.51%
Max EPS beat(4)71.58%
EPS beat(8)3
Avg EPS beat(8)-64.31%
EPS beat(12)6
Avg EPS beat(12)-35.62%
EPS beat(16)10
Avg EPS beat(16)-21.03%
Revenue beat(2)0
Avg Revenue beat(2)-48.85%
Min Revenue beat(2)-91.73%
Max Revenue beat(2)-5.97%
Revenue beat(4)1
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-91.73%
Max Revenue beat(4)163.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.32%
PT rev (3m)26.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-65%
EPS NY rev (3m)-65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-51.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.11
P/FCF 2.88
P/OCF 2.87
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.55
FCFY34.76%
OCF(TTM)0.55
OCFY34.84%
SpS0.31
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.38%
ROE -25.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.54%
FCFM 177.6%
ROA(3y)-21.2%
ROA(5y)-22.19%
ROE(3y)-32.63%
ROE(5y)-30.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.9%
GM growth 5YN/A
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 24.28%
Cap/Sales 0.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 5.26
Altman-Z -3.73
F-Score5
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)54.17%
Cap/Depr(5y)49.83%
Cap/Sales(3y)2.49%
Cap/Sales(5y)4.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-22.72%
EPS Next 2Y-6.37%
EPS Next 3Y15.29%
EPS Next 5Y-13.08%
Revenue 1Y (TTM)-23.4%
Revenue growth 3Y66.84%
Revenue growth 5YN/A
Sales Q2Q%-10.75%
Revenue Next Year-66.37%
Revenue Next 2Y-4.04%
Revenue Next 3Y2.48%
Revenue Next 5Y-1.06%
EBIT growth 1Y-14.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.23%
OCF growth 3YN/A
OCF growth 5YN/A